DE602004021713D1 - Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung - Google Patents

Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung

Info

Publication number
DE602004021713D1
DE602004021713D1 DE602004021713T DE602004021713T DE602004021713D1 DE 602004021713 D1 DE602004021713 D1 DE 602004021713D1 DE 602004021713 T DE602004021713 T DE 602004021713T DE 602004021713 T DE602004021713 T DE 602004021713T DE 602004021713 D1 DE602004021713 D1 DE 602004021713D1
Authority
DE
Germany
Prior art keywords
pharmaceutical formulations
short chain
sphingolipids
chain sphingolipids
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004021713T
Other languages
English (en)
Inventor
Robert Jan Veldman
Blitterswijk Wim J Van
Marcel Verheij
Gerben A Koning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HET NL KANKER I NETHERLAND
Original Assignee
HET NL KANKER I NETHERLAND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0326642A external-priority patent/GB0326642D0/en
Priority claimed from GB0326759A external-priority patent/GB0326759D0/en
Application filed by HET NL KANKER I NETHERLAND filed Critical HET NL KANKER I NETHERLAND
Publication of DE602004021713D1 publication Critical patent/DE602004021713D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE602004021713T 2003-11-14 2004-11-11 Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung Active DE602004021713D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326642A GB0326642D0 (en) 2003-11-14 2003-11-14 Pharmaceutical formulations
GB0326759A GB0326759D0 (en) 2003-11-17 2003-11-17 Pharmaceutical formulations and their preparation and use
PCT/IB2004/003886 WO2005046637A2 (en) 2003-11-14 2004-11-11 Pharmaceutical formulations employing short-chain sphingolipids and their use

Publications (1)

Publication Number Publication Date
DE602004021713D1 true DE602004021713D1 (de) 2009-08-06

Family

ID=34593738

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021713T Active DE602004021713D1 (de) 2003-11-14 2004-11-11 Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung

Country Status (6)

Country Link
US (2) US7915227B2 (de)
EP (1) EP1686959B1 (de)
AT (1) ATE434431T1 (de)
DE (1) DE602004021713D1 (de)
ES (1) ES2329374T3 (de)
WO (1) WO2005046637A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004021713D1 (de) * 2003-11-14 2009-08-06 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
US20080058274A1 (en) * 2004-11-15 2008-03-06 Yechezkel Barenholz Combination Therapy
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
PL1853303T3 (pl) * 2005-02-14 2016-05-31 Dpm Therapeutics Corp Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania
US7794722B2 (en) * 2006-06-30 2010-09-14 The Scripps Research Institute Adjuvants and methods of use
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CN101244038B (zh) * 2007-10-26 2010-12-08 吴念 稳定型阿霉素类脂质体及其制备方法
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
AR093275A1 (es) * 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
WO2014144365A1 (en) * 2013-03-15 2014-09-18 University Of Maryland, College Park Nano-liposomal formulations and methods of use
WO2016049250A1 (en) * 2014-09-24 2016-03-31 The Board Of Trustees Of The University Of Illinois Artificial platelets for treating catastrophic bleeding
WO2018146506A1 (en) * 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416872A (en) 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
GB8620361D0 (en) 1986-08-21 1986-10-01 Windleshaw Enterprises Ltd Pharmaceutical compositions
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
JP3499604B2 (ja) 1994-07-25 2004-02-23 財団法人神奈川科学技術アカデミー スフィンゴ糖脂質ミセルからなる薬物担体
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5800833A (en) * 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
US20010006648A1 (en) 1996-02-26 2001-07-05 Hitoshi Yamauchi Liposomes and liposomal dispersion
CA2320117A1 (en) * 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
JP2004501955A (ja) 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
DE602004021713D1 (de) * 2003-11-14 2009-08-06 Het Nl Kanker I The Netherland Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung

Also Published As

Publication number Publication date
US7915227B2 (en) 2011-03-29
US20070082855A1 (en) 2007-04-12
EP1686959A2 (de) 2006-08-09
EP1686959B1 (de) 2009-06-24
ES2329374T3 (es) 2009-11-25
ATE434431T1 (de) 2009-07-15
US20110150984A1 (en) 2011-06-23
WO2005046637A2 (en) 2005-05-26
WO2005046637A3 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
DE602004021713D1 (de) Pharmazeutische formulierungen mit kurzketten-sphingolipiden und ihre verwendung
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
CY1107166T1 (el) Μη-πολυμερεις λιποφιλες φαρμακευτικες συνθεσεις εμφυτευματων για ενδοφθαλμικη χρηση
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
CY1111458T1 (el) Μορφες δοσολογιας γενικως γραμμικης, αναβραζουσας, απο του στοματος φεντανυλης και μεθοδοι χορηγησης
CY1109240T1 (el) Συνδυασμος που περιλαμβανει βαλσαρτανη, αμλοδιπινη και υδροχλωροθειαζιδιο
DK1543063T3 (da) Medikament levering
CY1124650T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει ινσουλινη σε κρυσταλλικη μορφη καθως και σε διαλυτοποιημενη μορφη
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
NO20082097L (no) Farmasoytiske sammensetninger
ATE549016T1 (de) Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат

Legal Events

Date Code Title Description
8364 No opposition during term of opposition